drugset / Trial / NCT00167102

Alefacept in Patients With Severe Scalp Alopecia Areata

NCT00167102

RandomizedParallel-groupTriple-blindOther

Summary

The purpose of this study is to examine prospectively the safety and efficacy of alefacept in the treatment of subjects with severe alopecia areata of the scalp. Common features between psoriasis and alopecia areata, including immunologic and therapeutic aspects, suggest that alefacept, which has been shown to be a safe and statistically significant beneficial therapeutic modality for the treatment of psoriasis, may have therapeutic value in alopecia areata.

Timeline

Start
2005-07
Primary completion
2008-02
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Alefacept Protein / enzyme biologic 15 mg Intramuscular

Indications